Examining autistic traits and sensory profiles in children with Prader-Willi Syndrome
Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome
This study looks at how autistic traits and sensory experiences show up in children with Prader-Willi Syndrome to better understand their needs and see if early oxytocin treatment makes a difference.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 3 Years to 16 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06877715 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on children diagnosed with Prader-Willi Syndrome (PWS) to explore their autistic symptomatology and sensory profiles. It aims to identify the unique characteristics of autism in PWS, which is often overlooked in standard care. The study will involve psychological and sensory assessments, and it will also consider the effects of early oxytocin treatment on these traits. By aligning with recommendations for early intervention, the study seeks to improve understanding and management of PWS-related challenges.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 3 to 16 years with genetically confirmed Prader-Willi Syndrome.
Not a fit: Patients who have recently changed their psychotropic treatment or are unable to provide clear information may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better identification and tailored interventions for children with Prader-Willi Syndrome and associated autistic traits.
How similar studies have performed: While there is limited research specifically on PWS and autism, studies on similar neurodevelopmental disorders have shown the importance of early intervention and tailored assessments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Child with genetically confirmed PWS and identification of genetic subtype; * Child aged between 3 and 16 years; * Hospitalisation or multidisciplinary consultation planned for the child's routine follow-up at one of the investigating centres; * No parental/legal guardian objection. Exclusion Criteria: * Change in psychotropic treatment (start, change in dose or discontinuation) in the past 3 months; * Inability to provide clear information to parents/legal guardian; * Not covered by social security.
Where this trial is running
Toulouse
- Children Hospital — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Sophie Cabal — University Hospital of Toulouse
- Study coordinator: Nadege ALGANS
- Email: algans.n@chu-toulouse.fr
- Phone: 0561777204
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.